リンパ浮腫治療の世界市場：2024年～2031年

概要

世界のリンパ浮腫治療市場は、2023年に11億米ドルに達し、2024年から2031年の予測期間中にCAGR 9.5％で成長し、2031年には23億米ドルに達すると予測されています。

リンパ浮腫とは、通常身体のリンパ系を通じて排出されるタンパク質を多く含む体液の蓄積によって引き起こされる組織の腫脹を指します。リンパ浮腫は腕や脚に生じることが最も多いが、胸壁、腹部、頸部、生殖器にも生じることがあります。

リンパ節はリンパ系の重要な一部です。リンパ浮腫は、リンパ節を切除したり損傷したりするがん治療によって引き起こされることがあります。リンパ液の排出を阻害するあらゆる種類の問題がリンパ浮腫を引き起こす可能性があります。

リンパ浮腫の治療には通常、理学療法と、リンパ浮腫の影響を受けた部分から体液を移動させる衣服や包帯の組み合わせが含まれます。

市場力学：

促進要因

リンパ浮腫治療のための技術進歩の増加

世界のリンパ浮腫市場の需要は、複数の要因によって牽引されています。主な要因の一つは、ヘルスケアシステムにおける技術の進歩です。リンパ浮腫は慢性的な症状であり、通常はリンパ液の排出不足によって引き起こされます。

主要企業による革新的な技術の進歩は、市場の成長を後押しします。これらの効果的な進歩は、研究の発見を新たな治療に転換し、何百万人ものリンパ浮腫患者のケアを改善するのに役立っています。例えば、2022年10月、ImpediMed Limitedは、乳がん患者に対するリンパ浮腫の影響を軽減することに特化した、主要ながんセンターにおける同社のSOZOデジタルヘルスプラットフォームの使用拡大を発表しました。

さらに、リンパ浮腫の治療において先進的な研究開発を導入し、新しい治療法や医薬品を発売する主なプレーヤーは、この市場の成長を促進すると思われます。例えば、2023年4月、AIROS Medical, Inc.は、新しい蠕動式空気圧迫装置、リンパ浮腫治療用トランカルガーメントの販売許可を米国食品医薬品局（FDA）から取得したと発表しました。

また、2022年4月、KOYAメディカルは、下肢のリンパ浮腫と静脈疾患の治療用アクティブ・コンプレッション・システム「Dayspring」の米国での市販を発表しました。Dayspringは、米国食品医薬品局（FDA）の認可を受けた初の非空圧式能動的圧迫治療です。このように、上記の要因が市場の成長を後押ししています。

抑制要因

高額な治療費、幹細胞治療に伴う副作用、限られた治療オプション、個人の認識・診断不足などの要因が、市場の阻害要因になると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • リンパ浮腫治療のための技術進歩の増加
    • がん罹患率の増加、政府の取り組みと資金援助
  • 抑制要因
    • 治療方法の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析
• ロシア・ウクライナ戦争影響分析
• DMIの見解

第6章 タイプ別

• 原発性リンパ浮腫
• 続発性リンパ浮腫

第7章 治療法

• 除痛療法
• 手術療法
• 薬物療法
• レーザー療法
• その他

第8章 エンドユーザー別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第11章 企業プロファイル

• Kite Pharma
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Johnson and Johnson
• Sanofi S.A
• LGM Pharma
• Hubei Xunda Pharma
• Sigma Aldrich
• Midas Pharma
• Oishi Koseido Co. ltd
• Glentham Life Sciences
• Taro Pharmaceuticals

第12章 付録

Overview

The global lymphedema treatment market reached US$ 1.1 billion in 2023 and is expected to reach US$ 2.3 billion by 2031 growing with a CAGR of 9.5% during the forecast period 2024-2031.

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid that's usually drained through the body's lymphatic system. It most commonly affects the arms or legs, but can also occur in the chest wall, abdomen, neck, and genitals.

Lymph nodes are an important part of the lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage the lymph nodes. Any type of problem that blocks the drainage of lymph fluid can cause lymphedema.

Lymphedema treatment typically includes a combination of physical therapy and garments or bandaging that moves fluid from areas affected by lymphedema.

Market Dynamics: Drivers

Increasing Technological Advancements for Lymphedema Treatment

The demand for the global lymphedema market is driven by multiple factors. One of the key factors is the technological advancements in the healthcare system. Lymphedema is a chronic condition that is usually caused by insufficient lymphatic drainage.

The innovative technological advancements by key companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with lymphedema. For instance, in October 2022, ImpediMed Limited announced the expansion of the use of its SOZO Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients.

Moreover, key players introducing advanced research & developments in treating lymphedema and launching new therapies & drugs would drive this market growth. For instance, in April 2023, AIROS Medical, Inc. announced that it received U.S. Food and Drug Administration (FDA) clearance to market a new peristaltic pneumatic compression device, truncal garments for lymphedema treatment.

Also, in April 2022, Koya Medical announced the U.S. commercial availability of its Dayspring active compression system for the treatment of lymphedema and venous diseases in the lower extremities. Dayspring is the first non-pneumatic active dynamic compression treatment cleared by the U.S. Food and Drug Administration (FDA). Thus, the above factors help to boost the market growth.

Restraints

Factors such as the high cost of the treatment procedure, side effects associated with stem cell therapy treatment, limited treatment options, and lack of awareness & diagnosis among individuals, are expected to hamper the market.

Segment Analysis

The global lymphedema treatment market is segmented based on type, treatment, end users, and region.

The decongestive therapy segment accounted for approximately 43.2% of the global lymphedema treatment market share

The decongestive therapy segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment therapy globally have contributed to the growing demand for lymphedema treatment. According to clinicalTrials.gov, in July 2022, Gulhane School of Medicine conducted a clinical trial on the Effect of Metabolic Syndrome on Complex Decongestive Physiotherapy Outcomes in Lymphedema Patients. The aim is to compare the effectiveness of complex decongestive physiotherapy (KBF) in patients with and without metabolic syndrome.

Moreover, key players in the industry research studies in the treatment of lymphedema would drive this segment growth. For instance, in July 2023, Cairo University conducted a clinical trial on the Effect Of Complete Decongestive Therapy on Carpal Tunnel Syndrome Post Upper Limb Lymphedema (CDT). The patients receives complete decongestive therapy in the form of intermittent pneumatic compression, exercising, bandaging, and manual lymphatic drainage. Thus, the above factors help to accelerate the market growth.

Also, in May 2022, PureTech Health announced the presentation of additional data for PureTech's LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference. LYT-100 demonstrated a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels and observed improved tolerability of LYT-100. It is the potential treatment of conditions involving inflammation and fibrosis, including lung disease and disorders of lymphatic flow, such as lymphedema.

Geographical Analysis

North America accounted for approximately 41.2% of the global lymphedema treatment market share

North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of lymphedema, and rising breast cancer, in the U.S., and Canada driving the market growth.

As per Lymphatic Education & Research Network in 2024, up to 250 million people worldwide have lymphedema (LE) with an estimated 10 million living with lymphedema (LE) in the United States, up to 30% of breast cancer survivors acquire debilitating LE.

Moreover, in this region, a major key player's partnerships & collaborations, well-advanced healthcare system, and new product launches would propel this market growth. For instance, in June 2023, PAUL HARTMANN AG announced its partnership with Sigvaris for the innovative compression wraps and liners range that are used as compression therapy for the treatment of lymphedema.

Also, in October 2022, ImpediMed announced the U.S. launch of a lymphedema prevention program with Genesis Care, a global organization dedicated to the care of cancer patients.

Similarly, in March 2024, NHLBI helps launch the first NIH National Commission on Lymphatic Diseases. The creation of this lymphatics commission is a gratifying and revolutionary step in this very important and relatively neglected field of research.

Market Segmentation

By Type

• Primary Lymphedema
• Secondary Lymphedema

By Treatment

• Stem Cell Therapy
• Decongestive therapy
• Surgery
• Drug Therapy
• Laser Therapy
• Others

By End Users

• Hospital
• Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the lymphedema market include Kite Pharma, Johnson, and Johnson, Sanofi S.A, LGM Pharma, Hubei Xunda Pharma, Sigma Aldrich, Midas Pharma, Oishi Koseido Co. Ltd, Glentham Life Sciences, Taro Pharmaceuticals among others.

Key Developments

• In August 2023, Calamos Advisors LLC made a significant investment in Tactile Systems Technology, Inc. by acquiring 60,861 shares of the company's stock. The purchase amounted to approximately $999,000 and represented 0.26% ownership of Tactile Systems Technology. Tactile Systems Technology is a medical technology company dedicated to developing innovative devices for the treatment of conditions such as lymphedema, venous disorders, and pulmonary secretions retention.
• In June 2022, Hyperice, launched Normatec 3, the next evolution of the iconic Normatec series which uses dynamic air compression to advance everyday wellness and helps aid in faster recovery, and improved training. Normatec was developed to help people undergoing breast cancer treatment who often suffer from lymphedema caused by removal or damage to their lymph nodes.
• In May 2022, Hospice charity partners with AECC University College to provide new lymphoedema service. The initiative follows the success of Lewis-Manning Hospice Care's pilot mobile lymphoedema clinics by bringing its services closer to people's homes and making the service accessible and easy.

Why Purchase the Report?

• To visualize the global lymphedema treatment market segmentation based on type, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global lymphedema treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lymphedema treatment market report would provide approximately 69 tables, 70 figures, and 182 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End Users
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Technological Advancements for Lymphedema Treatment
    • 4.1.1.2. Increasing Prevalence of Cancer and Government Initiatives & Funding
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of the Treatment Procedure
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Primary Lymphedema
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Secondary Lymphedema

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Decongestive therapy
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Surgery
• 7.4. Drug Therapy
• 7.5. Laser Therapy
• 7.6. Others

8. By End Users

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 8.1.2. Market Attractiveness Index, By End Users
• 8.2. Hospital Pharmacy
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacy
• 8.4. Online Pharmacy
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Product Benchmarking
• 10.3. Company Share Analysis
• 10.4. Key Developments and Strategies

11. Company Profiles

• 11.1. Kite Pharma*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Johnson and Johnson
• 11.3. Sanofi S.A
• 11.4. LGM Pharma
• 11.5. Hubei Xunda Pharma
• 11.6. Sigma Aldrich
• 11.7. Midas Pharma
• 11.8. Oishi Koseido Co. ltd
• 11.9. Glentham Life Sciences
• 11.10. Taro Pharmaceuticals

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us